Goldline Pharmaceutical IPO
Bookbuilding IPO | ₹12.00 Cr | Listing at BSE SME
Closed
IPO Open
Tue, May 12, 2026
IPO Close
Thu, May 14, 2026
Price Band
₹41.00 to ₹43.00
Market Cap (Pre-IPO)
₹41.27 Cr
IPO Details
| IPO Date | May 12, 2026 to May 14, 2026 |
| Listing Date | May 19, 2026 |
| Face Value | ₹10.00 per share |
| Price Band | ₹41.00 to ₹43.00 |
| Lot Size | 3000 Shares (Minimum: ₹129,000.00) |
| Sale Type | Fresh Issue |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Issue Size | ₹12.00 Crores |
| Total Shares Offered | 2,700,000 shares |
| Fresh Issue | 2,562,000 shares |
| Offer For Sale | 2,700,000 shares |
Goldline Pharmaceutical IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Issue size |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII Shares Offered | Not more than 15% of the Net Issue |
Goldline Pharmaceutical IPO Lot Size
Investors can bid for a minimum of 6,000 shares and in multiples of 3,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 6,000 | ₹258,000 |
| Retail (Max) | 2 | 6,000 | ₹258,000 |
| S-HNI (Min) | 3 | 9,000 | ₹387,000 |
| S-HNI (Max) | 7 | 21,000 | ₹903,000 |
| B-HNI (Min) | 8 | 24,000 | ₹1,032,000 |
Goldline Pharmaceutical Financial Information (Restated Consolidated)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 26.28 | 22.93 | 19.39 |
| Total Income | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.83 | 1.81 | 0.26 |
| EBITDA | 5.83 | 4.30 | 2.19 |
| NET Worth | 10.35 | 7.87 | 5.89 |
| Reserves and Surplus | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 11.03 | 11.13 | 10.83 |
Amount in ₹ Cr
Key Performance Indicators
As of Tuesday, March 31, 2026| KPI | Values |
|---|---|
| ROE (Return on Equity) | 35.84% |
| ROCE (Return on Capital Employed) | 38.46% |
| Debt/Equity | 1.50 |
| RoNW (Return on Net Worth) | 27.38% |
| PAT Margin (Profit After Tax Margin) | 10.10% |
| EBITDA Margin | 20.79% |
| Price to Book Value | 3.47 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 4.11 | 2.95 |
| P/E (x) | 10.47 | 14.56 |
| Promoter Holding | 79.70% | - |
Company Promoters
- Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal are the company promoters.
Company Overview
Goldline Pharmaceutical – Company Overview
- Goldline Pharmaceuticals is engaged in the marketing and distribution of pharmaceutical products under the brand name “Goldline.”
Core Segments
- Goldline Pharma: Products for physicians, orthopedics, ENT, gastroenterology, neurology, and urology
- Goldline Cardinal: Products for diabetology, cardiology, endocrinology, and general physicians
- Goldline Aayushman: Pediatric and neonatology focused products
- Goldline InLife: Critical care and intensive care medicines
- Goldline Wellness: Supportive care products, including cancer therapy support
- The company follows an asset-light model, where medicines are manufactured through third-party manufacturers based on its specifications and market research.
- It works with 15 manufacturers and 7 distributors, supplying products to retailers, wholesalers, hospitals, and healthcare providers.
- The company markets products across multiple states including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
- Goldline focuses on specialty healthcare segments, quality compliance, and strong distribution partnerships to expand its pharmaceutical presence.
Company Strengths
- Experienced Promoters and Management Team with Industry Knowledge and a Track Record
- Asset-light Business Model and Competitive Products
- Scalable Business Model
- Wide and Diverse Range of Product Offerings
- Strong Supplier and Vendor Relationships
- Established Distribution Network
Use of Proceeds
| 1) | Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | 8.90 |
| 2) | General corporate purposes |
Objectives
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Goldline Pharmaceutical IPO Peer Comparison
Goldline Pharmaceutical peer comparison with similar listed entities. (As on March 31, 2026)| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Mono Pharmacare Ltd. | 1.75 | 1.75 | 17.66 | 12.57 | 9.90 | - | - |
| Chandra Bhagat Pharma Ltd. | 1.14 | 1.14 | 39.72 | 37.73 | 2.86 | - | - |
Quick Info
| Sector | Pharmaceutical |
| Exchange | BSE SME |
| Market Cap (Pre-IPO) | ₹41.27 Cr |
Important Dates
| IPO Open | May 12, 2026 |
| IPO Close | May 14, 2026 |
| Allotment Date | May 15, 2026 |
| Credit to Demat | May 18, 2026 |
| Listing Date | May 19, 2026 |
Lead Manager(s)
Cumulative Capital Pvt.Ltd.
Registrar
Description
- IPO Type: Book build issue aggregating to ₹11.61 crores.
- Issue Structure: Entirely a fresh issue of 0.27 crore shares totaling ₹11.61 crores.
- IPO Dates: The issue opens on May 12, 2026 and closes on May 14, 2026.
- Allotment Date: Expected to be finalized on May 15, 2026.
- Listing Details: Shares are proposed to be listed on the SME platform of BSE Limited (BSE SME) with a tentative listing date of May 19, 2026.
- Retail Investment Requirement: Minimum 2 lots (6,000 shares) amounting to approximately ₹2,58,000 (at upper price band).
- HNI Investment Requirement: Minimum 3 lots (9,000 shares) totaling around ₹3,87,000.
- IPO Price Band: ₹41 to ₹43 per equity share.
- Lot Size: 3,000 shares per lot.
This IPO offers investors an opportunity to participate in the pharmaceutical and healthcare sector, subject to market risks.